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Abstract
Background: A large number of oral squamous cell carcinomas (OSCCs) are believed to be 
preceded by oral potentially malignant disorders (OPMD) that have an increased likelihood of 
malignant transformation compared to clinically normal mucosa. This study was performed to 
identify differentially expressed genes between OPMDs that underwent malignant transformation 
(MT) and those that did not, termed ‘non-transforming’ (NT) cases. 
Methods: Total RNA was extracted from formalin-fixed paraffin-embedded tissue biopsies of 20 
OPMD cases with known clinical outcomes (10 MT vs. 10 NT). Samples were assessed for 
quantity, quality and integrity of RNA prior to sequencing. Analysis for differential gene 
expression between MT and NT was performed using statistical packages in R. Genes were 
considered to be significantly differentially expressed if the False Discovery Rate corrected p-
value was < 0.05. 
Results: RNA yield was variable but RNA purity was good (A260/A280 >1.90). Analysis of 
RNA-Sequencing outputs revealed 41 genes (34 protein-coding; 7 non-coding) that were 
significantly differentially expressed between MT and NT cases. The log2 fold change for the 
statistically significant differentially expressed genes ranged from -2.63 to 2.48, with 23 protein-
coding genes being downregulated and 11 protein-coding genes being upregulated in MT cases 
compared to NT cases.
Conclusion: Several candidate genes that may play a role in malignant transformation of OPMD 
have been identified. Experiments to validate these candidates are underway. It is anticipated that 
this work will contribute to better understanding of the aetiopathogenesis of OPMD and 
development of novel biomarkers.
Keywords: oral potentially malignant disorders; oral squamous cell carcinoma; RNA-Sequencing; 
malignant transformation
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Epidemiological studies estimate that more than 300,000 new cases and 145,400
deaths from oral cancers (inclusive of lip cancers) occur annually.1 Approximately two-thirds of 
the new oral cancer cases occurred in men, and around 77% of oral cancer deaths were in less 
developed nations.1 Most oral cancers are oral squamous cell carcinomas (OSCCs) and a 
proportion of OSCCs are believed to be preceded by clinical entities termed ‘oral potentially 
malignant disorders’ (OPMDs).2 OPMDs are defined as clinical disorders having an increased risk 
of developing OSCC in oral mucosa; either in recognisable lesions or clinically “normal” oral 
mucosa.2
There are several possible clinical outcomes for OPMD, the lesion remains unchanged, it increases 
in size, it regresses in size, it disappears completely or undergoes malignant transformation (MT). 
Several epidemiological studies conducted in different areas of the world have shown that most 
OPMD do not undergo MT although they may persist.2,3 A contemporary systematic review and 
meta-analysis described a mean overall MT rate of 12.1% in oral epithelial dysplasia (OED) whilst 
a recent systematic review found a 7.9% prevalence rate of MT in OPMD.3,4 Currently, there is no 
reliable method to determine the clinical outcome of patients with OPMDs. To compensate for the 
limitations in predicting malignant change, biomarkers have been sought based on an improved 
understanding of the underlying molecular pathogenesis of OSCC. Numerous individual 
biomarkers have been studied, but none have been validated for use in clinical practice. 
By studying differential gene expression (DGE) between normal and abnormal tissue, in-depth 
understanding of the genetic pathways involved in carcinogenesis can be elucidated. Studies based 
on DGE have allowed researchers to dissect and examine the cancer transcriptome in a way that 
was not possible using conventional molecular biological methods. DGE has also contributed to 
the paradigm shift away from single biomarkers towards the use of gene expression signatures for 
diagnosis or prognosis.
The ability to identify patient sub-groups with similar molecular patterns in various tumour types 
have enabled researchers to define new molecular cancer sub-types enhancing better targeted 
therapy and patient care. A prime example is breast cancer where at least five molecular sub-types 
with prognostic correlation were discovered. The findings were then further refined and validated 
resulting in a predictive gene signature.5 The lack of prognostic biomarkers in OPMD is a cogent A
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reason to perform DGE-based studies to identify gene signatures for early diagnosis, therapy or 
prognosis in OPMD to inform targeted therapy. A recent meta-analysis performed by De Cecco et 
al. (2015) demonstrated the usefulness of DGE studies in stratifying HNSCC into six sub-types 
characterized by their respective clinico-pathological features and dysregulation of relevant 
signalling pathways.6
There are very few DGE studies on OPMD or oral epithelial dysplasia (OED).7-11  As yet, only 
one truly investigated DGE between OPMD that transformed to OSCC and those that did not.7 
Saintigny et al (2011) proposed gene expression-based prediction models that showed superior 
prognostic accuracy when compared to models using clinico-pathologic risk factors.7 As such, 
further studies in DGE between OPMD that undergo malignant transformation versus those that 
do not would provide much needed insight into the molecular mechanisms that translate into 
malignant transformation in OPMDs.  
Whole transcriptome analysis is a major advancement in studying and understanding gene 
expression as it allows researchers to obtain a comprehensive view of the transcriptional profile at 
a given moment in time. A widely used method for profiling the whole transcriptome in a 
“snapshot” manner is RNA-Sequencing (RNA-Seq). As it captures the whole transcriptome, 
RNA-Seq is able to detect gene transcripts and is suitable for assessing genes that are differentially 
expressed between different disease states. In this study, we have used RNA-Seq as a discovery 
platform to identify transcripts of genes that may be involved in the malignant transformation of 
OPMD.
Materials and Methods
Patients
OPMD cases for this study were selected from a previously studied cohort of OPMD patients.12 A 
case was classified as having undergone MT when there was progression from an OPMD to oral 
squamous cell carcinoma (OSCC) after a period of six months or more from the time of the initial 
diagnosis of OPMD. 
The following exclusion criteria were applied: i) Previous history of head and neck cancer; ii) 
Previous history of radiotherapy to the head and neck region; iii) Patients with hereditary/acquired A
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conditions that are linked to an increased risk of head and neck SCC (such as ataxia telangiectasia, 
xeroderma pigmentosum, Fanconi anaemia etc); iv) Patients that were diagnosed as having 
chronic hyperplastic candidosis; v) Cases with incomplete/inconsistent records; vi) Cases with 
inadequate/damaged/unavailable FFPE tissue for analysis.
Demographic (age at diagnosis, sex) and clinico-pathological data (site, clinical diagnosis) were 
recorded for each patient. The clinical outcome and time to either malignant transformation or last 
follow-up was also recorded and calculated for the patients.  
Histopathological assessment
Archived haematoxylin and eosin (H&E)-stained sections of the cases identified from the OPMD 
database were retrieved and assessed to choose suitable formalin-fixed paraffin-embedded (FFPE) 
blocks from each case. Subsequently, selected FFPE blocks were retrieved from the Royal 
Victoria Infirmary Department of Cellular Pathology archives and 4 µm sections were prepared. 
H&E staining was performed on the DAKO CoverStainer (Agilent Technologies, USA). 
All histopathological assessments were performed following a modified three-tier system adapted 
from the work published by Speight et. al. (2015) involving three oral and maxillofacial 
pathologists.13. The cases were graded using the three-tiered (mild, moderate or severe) World 
Health Organization (WHO) 2017 classification and binary grading systems.2 The pathologists 
were blinded to clinical outcome of OPMD patients during the assessment and grading exercise. 
Total RNA extraction from formalin-fixed paraffin-embedded (FFPE) tissue
10 μm sections were cut from the FFPE blocks and collected in 2 ml microcentrifuge tubes. The 
number of sections per sample was dependent on the size of the tissue; 4 sections for small sized 
samples, 3 - 4 sections for medium sized samples, 2 - 3 sections for large sized samples and 1 – 2 
sections for very large sized samples. RNA extraction and purification were performed using the 
QIAGEN RNeasy FFPE kit following the manufacturer's protocol (QIAGEN, Manchester, UK). 
Following RNA extraction, the concentration and the quality of the isolated RNA were measured 
using a NanoDrop 2000 Spectrophotometer (Thermo Fisher Scientific, UK). The samples were then 
stored in a -80°C freezer prior to utilisation in downstream experiments.
Whole transcriptome sequencing - RNA sequencing (RNA-Seq) A
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Whole transcriptome sequencing was performed using Illumina’s Next Generation Sequencing 
RNA-Seq platform (Illumina, USA) following established protocols. RNA samples were assessed 
for quantity and integrity using the NanoDrop 8000 spectrophotometer V2.0 (Thermo Fisher 
Scientific, USA) and Agilent 2100 Bioanalyser (Agilent Technologies, Waldbronn, Germany). From 
each sample, 100 ng of total RNA was used to prepare RNA libraries using the KAPA Stranded 
RNASeq Kit with RiboErase (KAPA Biosystems, Massachusetts, USA). Prior to first strand cDNA 
synthesis, fragmentation was carried out using incubation conditions recommended by the 
manufacturer for degraded samples (65°C for 1 minute), and 14 cycles of PCR were performed for 
final library amplification. The libraries produced were quantified using the Qubit 2.0 
spectrophotometer (Life Technologies, California, USA) and assessment of the average fragment 
size was performed using the Agilent 2200 TapeStation (Agilent Technologies, Waldbronn, 
Germany). The Illumina NextSeq®500 (Illumina Inc., Cambridge, UK) was used to generate 75 bp 
paired-end reads for each library. 
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics for Windows version 24 (IBM 
Corp., Armonk, N.Y., USA) and the R Environment for Statistical Computing version 3.2 (R 
Foundation for Statistical Computing, Vienna, Austria). A variety of methods were used to assess 
and analyse the data. Continuous data were always assessed for normality of distribution prior to 
choosing appropriate statistical tests. Parametric and non-parametric tests were used for initial 
analysis of demographic, clinical, pathological and molecular variables. For continuous data, 
descriptive results were appropriately expressed as either median with interquartile range (IQR) or 
mean with standard deviation (SD) Statistical significance was defined at the 5% level. 
Confidence intervals (CI) at the 95% confidence level were reported where relevant. 
Bioinformatic analysis of RNA-Seq data
FastQ files generated from the sequencing runs were downloaded from the Illumina server using 
BaseMount, the command line interface for Illumina BaseSpace. Read quality of the FastQ files 
generated from the sequencing run were assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and MultiQC (http://multiqc.info) was 
used to obtain summary statistics for quality control tests on the read quality. Reads were quantified 
against transcripts using “Kallisto”.14A
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To obtain gene-level counts, a package from the R statistical programming language (R Foundation 
for Statistical Computing, Vienna, Austria), “tximport” was used. Gene annotation was obtained 
from Ensembl transcript IDs using the R package “biomaRt”.15
The R package DESeq2 was used for normalisation and testing for differential gene expression by 
use of negative binomial generalised linear models.16 Genes were considered to be significantly 
differentially expressed when the False Discovery Rate (FDR) using the Benjamini-Hochberg 
method corrected p-value was less than 0.05. A hypergeometric test was carried out to assess over-
representation of gene ontology (GO) terms amongst genes found to be significantly differentially 
expressed. The R package 'GOStats' was used to implement this test.17
Ethics
This study was approved by the National Research Ethics Service Committee Northeast 
(Evaluation of the prognostic potential and functional significance of biomarkers in oral cancer; 
NRES Committee Northeast – Sunderland 11/NE/0118) and complies with UK legislation and 
guidelines.
Results
Clinical parameters
Twenty cases (10 malignant transforming vs 10 non-transforming cases) with complete clinical 
data and applicable RNA for the experiment were selected for total RNA sequencing. The 
demographic, clinical and histopathological characteristics of the cases are shown in Table 1. 
None of the clinical or pathological features were significantly correlated with clinical outcome. 
The cohort was composed predominantly of males and patients aged more than 50 years at 
diagnosis. The median time to MT was 17 months (IQR: 42.75 months).
Differential gene expression (DGE)
All samples passed the quality control assessments to proceed for downstream analysis. Reads 
were assessed using FastQC and overall quality was high. RNA yield was variable but RNA purity 
was good (A260/A280 >1.90). As expected, the RNA was highly degraded (RIN 1.4 - 2.6). 
Bioinformatic analysis of RNA-Seq outputs revealed 41 genes that were significantly A
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differentially expressed between MT and NT cases (Table 2). The log2 fold change for the 
statistically significant differentially expressed genes ranged from -2.63 to 2.48, with 27 genes 
being downregulated and 14 genes being upregulated in MT cases compared to NT cases (Table 
2). When the statistically significant gene list from our study was compared to the 2182 genes 
associated with oral cancer risk from the study by Saintigny et al (2011)7, there were only 4 genes 
that overlapped: CYP19A1, HIST1H2AJ, CCDC129 and MUC16. However, these four genes were 
not in the gene-signature based predictive models developed by Saintigny et al (2011).7
GO enrichment analysis
To discover the functions of the differentially expressed genes, we performed GO enrichment 
analysis (Supplementary table 1). Twenty of the most significant GO biological process (GOBP) 
terms associated with the identified significantly differentially expressed genes are listed in Table 
3. Of these, three GOBP terms were noted to have a high degree of association with oral 
carcinogenesis: Regulation of response to wounding (Genes: IER3, CD46 and FAM46A), 
regulation of response to DNA damage stimulus (Genes: IER3, SPIDR and MUC1), and regulation 
of Notch signalling pathway (Genes: DLX2 and CD46).
Discussion
Using RNA-Seq technology, our study has identified several novel differentially expressed genes 
that are associated with malignant transformation of OPMDs. The one previous study that 
similarly assessed DGE in OPMD  used microarray technology.7 Although we identified four of 
the same genes (CYP19A1, HIST1H2AJ, CCDC129 and MUC16), most of the statistically 
significant genes from our study do not overlap with the gene list (2182 in total) of the study by 
Saintigny et al (2011).7 This could possibly be due to the following reasons: i) patient 
heterogeneity; ii) tissue heterogeneity; iii) molecular heterogeneity of OPMDs; iv) treatment 
heterogeneity; v) different gene expression analysis platforms employed; vi) differences in 
bioinformatic analysis methods/pipeline; vii) sample size. Furthermore, the patient cohort in the 
Saintigny et al (2011) study were enrolled in a chemo-preventive trial for treatment of leukoplakia 
which may have influenced the outcome of the OPMD as well as the gene expression profile.7
A recent study by Conway et al (2015) also employed RNA-Seq to assess DGE in “normal”, OED 
and OSCC tissues however, all three tissue states (“normal”, OED and OSCC) were obtained from A
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the same excision specimen.8 Due to the well-recognised theory of field change in OPMD patients, 
it is understood that histologically “normal” tissue may not be molecularly “normal” and free from 
molecular change which introduces a confounder to the results obtained by Conway et al (2015). 
This confounding problem of normal epithelial tissue affects the majority of published gene 
expression studies involving OPMD and OSCC. Such studies may only provide an approximation 
of the molecular events that take place during malignant transformation of OPMD. 
The relatively small number of significantly differentially expressed genes identified in our study 
highlights the high degree of similarity between cases that undergo MT and those that do not. This 
finding is consistent with the overall clinico-pathological features of OPMDs whereby it is 
difficult to accurately predict the clinical outcome of a patient with OPMD. Instead of focusing too 
much on individual genes, more emphasis should be placed on the pathways and biological 
processes involved.
Three of the GOBP terms found from the enrichment analysis; “regulation of response to DNA 
damage stimulus”, “regulation of response to wounding” and “regulation of Notch signalling 
pathway”, have been shown to be associated with carcinogenesis and have some degree of 
association with one another.18-21 The relationship between DNA damage response (DDR) and 
carcinogenesis is one that is well established, and in recent years there has been interest in the 
association between regulation of DDR and the regulatory effect of the Notch signalling pathway 
on DDR.22,23 The association between regulation of wounding, cancer and the Notch signalling 
pathway is also one that is being studied with renewed interest in recent years, consistent with the 
hypothesis that cancer is an “over-healing wound”.18 
Although promising, the role of the Notch signalling pathway in head and neck cancers is quite 
complex as it has been shown to be able to exert both tumour suppressive and oncogenic 
effects.19,21 Mutations in Notch pathway genes has been previously described in head and neck 
squamous cell carcinoma with much work being centred around NOTCH1.19,24 Recent findings are 
more supportive of Notch as a tumour suppressor especially in head and neck squamous cell 
carcinoma as loss of Notch signalling has been shown to affect regulation of cell fate decisions in 
stem cells and stromal remodelling.19,24-26 However, the role of Notch signalling in oral A
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carcinogenesis specifically with regard to clinical outcome of OPMDs has yet to be fully 
elucidated.
The two significant genes from our study related to regulation of Notch signalling pathway were 
DLX2 and CD46. Our results showed that DLX2, a homeobox gene that is involved in embryonic 
development, was overexpressed in cases that underwent MT compared to non-transforming 
cases. Increased expression of DLX2  has been shown recently to be overexpressed in breast and 
ovarian cancers as well as advanced stages of gastric adenocarcinoma suggesting a potential role 
in carcinogenesis.27-29 The study by Lee et. al. (2011) suggests that DLX2 may be involved in 
tumour progression via metabolic-stress induced necrosis.28 DLX2 has also been implicated in 
transforming the role of transforming growth factor  (TGF) from a tumour-suppressor to a 
tumour-promoter by increasing the expression of the mitogenic transcription factor c-Myc, directly 
suppressing TGF receptor II and reducing expression of cell-cycle inhibitor p21CIP1.29 The role of 
DLX2 in oral carcinogenesis, however, is currently unknown.
Decreased expression of CD46 that encodes for a complement regulatory protein (a membrane co-
factor protein) was detected in cases that underwent malignant transformation. CD46 is also 
known as complement restriction factor as it facilitates inactivation of C3b and C4b of the 
complement system. Interestingly, other studies have shown that CD46 together with other 
complement restriction factors such as CD55 and CD59 are expressed at higher levels in head & 
neck cancer tissue compared to non-tumour tissue proposing that these proteins may play a role in 
tumour evasion of the complement system.30 The decreased expression of CD46 observed in our 
study is different to that seen in OSCCs suggesting that CD46 is dynamically expressed during 
oral carcinogenesis with possible temporal differences in expression before, during and after 
malignant transformation. 
Archived formalin-fixed paraffin-embedded (FFPE) tissues are an invaluable resource that can be 
successfully used for molecular-based assays despite the degradation that often accompanies 
fixation and embedding of tissues in paraffin wax. Our study adds to the increasing body of work 
on utilisation of FFPE material for gene expression studies.
One of the limitations of our study is the relatively small number of cases included compared to 
the study by Saintigny et al (2011) that had an 86-patient cohort.7 This was due to strict quality A
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control resulting in exclusion of poor quality RNA samples. Another limitation is that gene 
expression studies only allow a snapshot of the transcriptomic profile at a given point in time, and 
as such is a very simplistic and static representation of a dynamic temporal process. Furthermore, 
an OPMD that was categorised as being a non-transforming case may eventually undergo MT. 
However, RNA-Seq analysis for this study was to serve only as an initial broad overview of the 
transcriptomic differences between OPMD cases that undergo MT and those that do not.
In summary, our study has identified candidate genetic pathways that may play a role in malignant 
transformation of OPMD. Experiments to validate these pathways and relevant genes are currently 
underway, and it is anticipated that this work will contribute to better understanding of the 
pathogenesis of OPMD and the development of novel prognostic biomarkers.
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Table 1. Characteristics of OPMD cases according to clinical outcome (n = 20) 
Characteristic 
Non-transforming 
n=10 
Malignant 
transforming 
n=10 
p-value 
Age [Mean ( SD)] 55.7 (14.86) 60.0 (12.41) 0.491
†
 
Sex 
Male 9 7 
0.582‡ 
Female 1 3 
Site of OPMD 
Tongue 4 3 
1.000‡ 
Other sites 6 7 
OPMD 
Leukoplakia 9 8 
1.000‡ 
Erythroleukoplakia 1 2 
OED grading 
(WHO 2017) 
Mild 3 3 
0.635
§
 Moderate 1 3 
Severe 6 4 
Binary OED 
grading 
Low-grade 3 3 
1.000‡ 
High-grade 7 7 
†
Independent t-test; ‡Fisher’s Exact test; §Pearson’s Chi- square test; SD = Standard deviation  
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Table 2. Significant differentially expressed genes associated with malignant transformation 
of OPMD 
Ensembl gene ID 
HGNC 
symbol 
Gene biotype 
Log2 fold 
change 
FDR 
[BH p-value] 
ENSG00000196805 SPRR2B Protein coding 2.48 0.015 
ENSG00000283029 NA Non-coding 2.44 0.015 
ENSG00000115844 DLX2 Protein coding 2.30 0.015 
ENSG00000229035 SPRR2C Unprocessed pseudogene 2.28 0.015 
ENSG00000223802 CERS1 Protein coding 2.19 0.044 
ENSG00000166165 CKB Protein coding 2.11 0.015 
ENSG00000137869 CYP19A1 Protein coding 2.10 0.046 
ENSG00000235852 NA Antisense 2.00 0.019 
ENSG00000186648 LRRC16B Protein coding 1.79 0.030 
ENSG00000276368 HIST1H2AJ Protein coding 1.78 0.037 
ENSG00000123416 TUBA1B Protein coding 1.72 0.025 
ENSG00000137331 IER3 Protein coding 1.61 0.046 
ENSG00000066248 NGEF Protein coding 1.58 0.031 
ENSG00000127824 TUBA4A Protein coding 1.48 0.015 
ENSG00000162836 ACP6 Protein coding -1.05 0.031 
ENSG00000164808 SPIDR Protein coding -1.32 0.025 
ENSG00000117335 CD46 Protein coding -1.43 0.031 
ENSG00000111670 GNPTAB Protein coding -1.44 0.037 
ENSG00000135338 LCA5 Protein coding -1.45 0.035 
ENSG00000166432 ZMAT1 Protein coding -1.47 0.020 
ENSG00000181804 SLC9A9 Protein coding -1.67 0.026 
ENSG00000204789 ZNF204P Processed pseudogene -1.78 0.037 
ENSG00000165186 PTCHD1 Protein coding -1.79 0.036 
ENSG00000112773 FAM46A Protein coding -1.80 0.037 
ENSG00000139292 LGR5 Protein coding -1.82 0.046 
ENSG00000185499 MUC1 Protein coding -1.83 0.026 
ENSG00000214290 COLCA2 Protein coding -1.83 0.016 
ENSG00000267395 DM1-AS Antisense -1.86 0.033 A
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Ensembl gene ID 
HGNC 
symbol 
Gene biotype 
Log2 fold 
change 
FDR 
[BH p-value] 
ENSG00000196724 ZNF418 Protein coding -1.91 0.019 
ENSG00000177707 NECTIN3 Protein coding -2.01 0.026 
ENSG00000115648 MLPH Protein coding -2.03 0.019 
ENSG00000279387 NA NA -2.12 0.019 
ENSG00000180347 CCDC129 Protein coding -2.19 0.020 
ENSG00000235902 NA Antisense -2.21 0.024 
ENSG00000115112 TFCP2L1 Protein coding -2.22 0.015 
ENSG00000116039 ATP6V1B1 Protein coding -2.31 0.025 
ENSG00000177685 CRACR2B Protein coding -2.33 0.015 
ENSG00000134398 ERN2 Protein coding -2.41 0.015 
ENSG00000167165 UGT1A6 Protein coding -2.44 0.015 
ENSG00000107807 TLX1 Protein coding -2.46 0.016 
ENSG00000181143 MUC16 Protein coding -2.63 0.015 
FDR = False discovery rate; BH = Benjamini-Hochberg. False Discovery Rate was calculated 
using Benjamini-Hochberg method and significance set at the 5% level (p < 0.05). HGNC = 
Human Genome Organisation Gene Nomenclature Committee. NA = not available. Genes 
that overlap with the gene-list from the study by Saintigny et al (2011) are underlined.
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Table 3. Twenty most significant GOBP terms associated with malignant transformation of 
OPMD 
 
GOBP ID p-value Count Term 
GO:2001311 0.002 1 lysobisphosphatidic acid metabolic process 
GO:0010677 0.003 2 negative regulation of cellular carbohydrate metabolic 
process 
GO:1903034 0.003 4 regulation of response to wounding 
GO:2001020 0.003 3 regulation of response to DNA damage stimulus 
GO:0045912 0.004 2 negative regulation of carbohydrate metabolic process 
GO:0051084 0.004 2 'de novo' posttranslational protein folding 
GO:0016256 0.004 1 N-glycan processing to lysosome 
GO:0021893 0.004 1 cerebral cortex GABAergic interneuron fate commitment 
GO:0006458 0.004 2 'de novo' protein folding 
GO:0016266 0.005 2 O-glycan processing 
GO:0010760 0.006 1 negative regulation of macrophage chemotaxis 
GO:0021882 0.006 1 regulation of transcription from RNA polymerase II 
promoter involved in forebrain neuron fate commitment 
GO:0072757 0.006 1 cellular response to camptothecin 
GO:0006885 0.006 2 regulation of pH 
GO:0008593 0.007 2 regulation of Notch signalling pathway 
GO:0021898 0.008 1 commitment of multipotent stem cells to neuronal lineage 
in forebrain 
GO:0043382 0.008 1 positive regulation of memory T cell differentiation 
GO:0072710 0.008 1 response to hydroxyurea 
GO:0072711 0.008 1 cellular response to hydroxyurea 
GO:1901563 0.008 1 response to camptothecin 
GOBP = Gene Ontology Biological Process; ID = Identifier 
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